Your browser doesn't support javascript.
loading
Factors Associated With Human Papillomavirus Vaccine Series Completion Among Adolescents.
Mansfield, Lisa N; Silva, Susan G; Merwin, Elizabeth I; Chung, Richard J; Gonzalez-Guarda, Rosa M.
Afiliación
  • Mansfield LN; Duke University School of Nursing, Duke University, Durham, North Carolina. Electronic address: lmansfield@mednet.ucla.edu.
  • Silva SG; Duke University School of Nursing, Duke University, Durham, North Carolina.
  • Merwin EI; College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, Texas.
  • Chung RJ; Duke University School of Medicine, Duke Department of Pediatrics, Duke University, Durham, North Carolina.
  • Gonzalez-Guarda RM; Duke University School of Nursing, Duke University, Durham, North Carolina.
Am J Prev Med ; 61(5): 701-708, 2021 11.
Article en En | MEDLINE | ID: mdl-34256974
ABSTRACT

INTRODUCTION:

Most cancers associated with the human papillomavirus are preventable through vaccination. However, adolescent series completion rates are at 75.8%. Two vaccine doses are recommended for adolescents, but factors influencing 2-dose series completion are not well explored. The purpose of this study is to examine individual-level and community-level factors associated with timely human papillomavirus vaccine series completion among adolescents in the Southeastern U.S.

METHODS:

Series completion was assessed from January 2018 to February 2019 among a cohort of adolescents initiating vaccination in 2017. Factors influencing overall series completion and timely series completion were assessed using multivariable logistic regression.

RESULTS:

Among the sample, 64.4% completed the vaccine series and 53.8% completed it timely (e.g., 14 months). Higher odds of series completion were among adolescents who were younger at vaccine initiation (AOR=1.94, 95% CI=1.50, 2.50), who traveled moderate distances to the clinic (AOR=1.62, 95% CI=1.03, 2.56), and who lived in low-deprivation neighborhoods (AOR=1.85, 95% CI=1.31, 2.60), and lower among Hispanic (AOR=0.62, 95% CI=0.45, 0.87) and non-Hispanic Black (AOR=0.66, 95% CI=0.54, 0.81) adolescents and among those without private insurance (AOR=0.68, 95% CI=0.56, 0.83). Timely series completion resulted in similar findings; however, lower odds were among Hispanic (AOR=0.63, 95% CI=0.43, 0.95) and non-Hispanic Black (AOR=0.68, 95% CI=0.50, 0.92) adolescents than among non-Hispanic other adolescents.

CONCLUSIONS:

Individual-level and community-level factors continue to influence adolescent series completion, despite a reduction in doses. Future research is needed to understand racial/ethnic and regional disparities in human papillomavirus vaccine series completion and to develop interventions to promote series completion.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Risk_factors_studies Límite: Adolescent / Humans Idioma: En Revista: Am J Prev Med Asunto de la revista: SAUDE PUBLICA Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Risk_factors_studies Límite: Adolescent / Humans Idioma: En Revista: Am J Prev Med Asunto de la revista: SAUDE PUBLICA Año: 2021 Tipo del documento: Article